PD42-01 RESIDUAL MUSCLE-INVASIVE DISEASE AT CYSTECTOMY IS NOT ACCURATELY PREDICTED BY POST-CHEMOTHERAPY RESTAGING PROTOCOLS INCLUDING DNA DAMAGE RESPONSE GENE MUTATION ANALYSIS

INTRODUCTION AND OBJECTIVE:The standard of care for eligible patients with muscle-invasive bladder cancer (MIBC) includes neoadjuvant cisplatin-based chemotherapy (NAC), followed by radical cystect...